Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Teva

Buy These 2 Growth Stocks Before They Boom

The red-hot inflation and the Fed’s hawkish stance are raising the possibility of a recession. However, historical trends suggest that the market could experience a rebound later this month or early next month. So, we think it could be wise to invest in growth stocks Teva Pharmaceutical (TEVA) and Forrester…

StockNews.com

Blame the Government for the Adderall Shortage

Limiting the supply of a controlled substance does not remove demand. Users simply look elsewhere, including more unsavory sources.

Reason

US shortage of Adderall is due to increased demand, FDA and drug-makers say

FDA says supply does not meet demand and drug-maker says backorders are due to ‘significant rise’ in prescription rates

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

Los Angeles Times

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

1 Stock Warren Buffett Might Have Sold Too Soon

Warren Buffett’s diversified holding company Berkshire Hathaway exited its position in drugmaker TEVA by the end of 2021 at a loss of approximately $365 million on its four-year-long bet. However, Buffett appears to have exited to stock too soon as TEVA witnessed a significant reversal this year, gaining 34.5% year-to-date.…

StockNews.com

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27

Reuters Monkeypox Emergency Could Last Months, According To Experts

Benzinga

Teva Pharmaceutical will pay over $4 billion in opioid settlement

Teva Pharmaceutical Industries Ltd. said it had agreed to pay more than $4 billion to resolve thousands of lawsuits filed against the drugmaker by state and local governments over its highly addictive opioid painkillers.

Tribune News Service

3 Stocks to Grab Before They Potentially Turn Around

Concerns over red-hot inflation and the Fed’s hawkish stance is raising the possibility of a recession. However, BofA believes the ongoing bear market provides attractive opportunities for long-term investors. So, we think it could be wise to invest in Zoom Video (ZM), Teva Pharmaceutical (TEVA), and Trulieve Cannabis (TCNNF) which…

StockNews.com

Allergan, Teva to pay $54M in San Francisco opioid lawsuit

Opioid makers Allergan and Teva have agreed to pay $54 million in cash and overdose reversal drugs to settle a federal lawsuit brought by San Francisco

The Independent UK

3 Top-Rated Israeli Stocks to Add to Your Watchlist

Amid the uncertainties surrounding the U.S. economy, we think it could be wise to invest in quality Israeli stocks to cash in on the country’s favorable macroeconomic trends. Shares of Israel-based companies Teva (TEVA), ZIM (ZIM), and NICE (NICE) could be solid additions to one’s portfolio, given their fundamental strength.…

StockNews.com

Golden Cross Appears Before Teva Pharmaceutical Indus Investors

If history is any guide, there may be good fortune ahead for shares of Teva Pharmaceutical Indus (NYSE:TEVA). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Teva, Allergan Settle Opioid Lawsuit With West Virginia

U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has reached an agreement with the Attorney General of West Virginia that settles the state's opioid-related claims.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Deckers Outdoor Shares Jump After Solid Q4 Results

Deckers Outdoor Corp (NYSE:DECK) reported fourth-quarter net sales growth of 31.2% year-over-year to $736 million, +31.7% on a constant currency basis, beating the consensus of $639.20 million. Wholesale net sales increased 37.6% Y/Y to $448.8 million, and Direct-to-Consumer increased 22.2% Y/Y to $287.2 million. Comparable DTC net sales increased 19.3% Y/Y. Sales…

Benzinga

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients…

StockNews.com

Teva Pharmaceutical Industries: Why Investors Should Buy the Dip

Shares of Teva Pharmaceutical (TEVA) have plunged in price due to the company’s weak financials and its reduction of its top-line guidance. However, can the stock rebound by the company leveraging its broad product and services portfolio? Read on. Let’s find out.

Benzinga

4 Analysts Have This to Say About Teva Pharmaceutical Indus

Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and AbbVie Inc's (NYSE:ABBV) Allergan Plc are willing to pay more than $5 billion combined to resolve more than 3,500 lawsuits filed over highly addictive opioid painkillers, according to three people familiar with settlement talks. The people said the companies have been in mediation talks with plaintiffs for more than a year. …

Benzinga

Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise

Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) Q1 sales reached $3.66 billion, shrinking 8% Y/Y, missing the consensus of $3.75 billion. The decrease is mainly due to lower revenues from generic products in North America and Copaxone, partially offset by higher revenues from Anda and generic products in the Europe segment. The adjusted gross…

Benzinga

Recap: Teva Pharmaceutical Q1 Earnings

Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Input

The 10 best hiking sandals that won’t break while you’re backpacking

It's time to ditch the flip-flops and buy a pair of sandals that can survive surf, sand, mud, and more.

Benzinga

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

FDA Rejects Teva - MedinCell's Schizophrenia Candidate

Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) U.S. affiliate and MedinCell SA (OTC:MDCLF) have received FDA Complete Response Letter (CRL) regarding TV-46000/mdc-IRM for schizophrenia. The drug candidate is risperidone extended-release injectable suspension for subcutaneous use. Teva is reviewing its next steps based on the letter and will work closely with FDA to address their recommendations. Related: Teva Reports…

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.